Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LX101 in Leber's Congenital Amaurosis (Expanded Study)
NCT06024057Not yet recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Sep 2023
- Primary completion
- Sep 2028
- Modality
- Gene Editing, Gene Silencing, Monoclonal Antibodies
01
Overview
Open-label, single-arm trial of 765IGF-MTX in Leber congenital amaurosis (LCA), sponsored by Shanghai General Hospital. Primary endpoint: Local and systemic safety assessment at 52 weeks. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
765IGF-MTX
03
Conditions
Leber congenital amaurosis (LCA)
Beyond the preview
Go deeper on NCT06024057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06024057.